Candriam SCA
LBRX icon

Candriam SCA’s LB Pharmaceuticals LBRX Stock Holding History

Candriam SCA’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.9M Buy
+284,233
New +$11.7M 0.05% 261

Other funds holding LBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Meyer Handelman Company
Meyer Handelman Company Rye Brook, New York $3.49B AUM 26.82% 1-Year Est. Return

Candriam SCA's LBRX Position: Q3 2026 in Review

Candriam SCA opened a new position in LB Pharmaceuticals (LBRX) in Q3 2026: 284,233 shares worth $10.9M. The stake represents 0.05% of the portfolio and ranks #261 among its holdings.

36 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

  • Candriam SCA held 284,233 shares of LB Pharmaceuticals worth $10.9M as of Q3 2026.
  • LB Pharmaceuticals was a new Candriam SCA position in Q3 2026.
  • LB Pharmaceuticals made up 0.05% of Candriam SCA's portfolio in Q3 2026, its #261 holding.
  • 36 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.